Deferasirox
Based on 15 publication(s) in Google Scholar
Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.86%
- No. CAS: 201530-41-8
- Fòrmula: C21H15N3O4
- Peso molecular:373.36
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Deferasirox
More- J Clin Invest. 2025 Jul 1;135(17):e181881. [Abstract]
- Phytomedicine. 2024 Dec:135:156139. [Abstract]
- Oncogene. 2026 Jul;45(27):2727-2742. [Abstract]
- Antioxidants (Basel). 2024 Mar 29;13(4):424. [Abstract]
- Antioxidants (Basel). 2020 Aug 14;9(8):753. [Abstract]
- Free Radic Biol Med. 2026 Jul 14:255:16-34.
- Cell Rep. 2025 Aug 21;44(9):116186. [Abstract]
- Environ Health. 2025 Nov 28，XXXX(XXX).
- Cells. 2019 Dec 20;9(1):31. [Abstract]
- FASEB J. 2026 Mar 31;40(6):e71636. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Metallomics. 2024 Oct 4;16(10):mfae044. [Abstract]
- Gene. 2022 Aug 5:834:146609. [Abstract]
- Wayne State University. 2025.
- Bioengineered. 2022 Mar;13(3):6627-6637. [Abstract]
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DLD-1 | IC50 |
3.4 μM
Compound: 99
|
Antiproliferative activity against human DLD-1 cells assessed as reduction in cell proliferation
Antiproliferative activity against human DLD-1 cells assessed as reduction in cell proliferation
|
[PMID: 33445154] |
| Fibroblast | IC50 |
100 μM
Compound: Deferasirox
|
Cytotoxicity against human foreskin fibroblasts after 96 hrs by MTT assay
Cytotoxicity against human foreskin fibroblasts after 96 hrs by MTT assay
|
[PMID: 20005708] |
| HL-60 | GI50 |
5.5 μM
Compound: 27a
|
Antiproliferative activity against human HL-60 cells
Antiproliferative activity against human HL-60 cells
|
[PMID: 35838529] |
| KYSE-150 cell line | GI50 |
3.3 μM
Compound: 27a
|
Antiproliferative activity against human KYSE-150 cells
Antiproliferative activity against human KYSE-150 cells
|
[PMID: 35838529] |
| MDA-MB-231 | IC50 |
4 μM
Compound: Deferasirox
|
Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay
|
[PMID: 20005708] |
| MIA PaCa-2 | IC50 |
10 μM
Compound: Deferasirox
|
Cytotoxicity against human MIAPaCa2 cells after 96 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 96 hrs by MTT assay
|
[PMID: 20005708] |
| NCI-H460 | IC50 |
20.36 μM
Compound: DFX
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
|
[PMID: 34292737] |
| NCI-H460 | IC50 |
98.35 μM
Compound: DFX
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 34292737] |
| SK-N-MC | IC50 |
20.54 μM
Compound: 3
|
Toxicity in human SK-N-MC cells by MTT method
Toxicity in human SK-N-MC cells by MTT method
|
[PMID: 20041672] |
| SW480 | IC50 |
3.9 μM
Compound: 99
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell proliferation
Antiproliferative activity against human SW480 cells assessed as reduction in cell proliferation
|
[PMID: 33445154] |
In Vitro
In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower[1]. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent[2]. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 201530-41-8
-
Appearance Solid
-
Peso molecular 373.36
-
Fòrmula C21H15N3O4
-
Color White to light brown
-
SMILES
O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C4=CC=CC=C4O)C=C1
-
Synonyms
ICL 670
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
J Clin Invest
Iron supplementation alleviates pathologies in a mouse model of facioscapulohumeral muscular dystrophy. [Abstract]2025 Jul 1;135(17):e181881. PMID: 40591405 -
Phytomedicine
Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis. [Abstract]2024 Dec:135:156139. PMID: 39423479 -
Oncogene
2026 Jul;45(27):2727-2742. PMID: 42243330 -
Antioxidants (Basel)
2024 Mar 29;13(4):424. PMID: 38671872
Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Mar 29;13(4):424. [Abstract]
Western blotting was conducted to assess the levels of autophagic markers (LC3B, ATG5, ATG12, and ATG16L1) in lysates of Sup-B15 and Molt-4 cells after Deferasirox (100 nM, 24 h) treatment.
Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Mar 29;13(4):424. [Abstract]
Intracellular ROS levels were measured as fold increases in fluorescence relative to the negative control after 0, 1, 2, 4, and 8 h exposures of Sup-B15 cells to Deferasirox (100 nM) treatment.
-
Antioxidants (Basel)
Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in Plasmodium falciparum-Parasitized Erythrocytes. [Abstract]2020 Aug 14;9(8):753. PMID: 32824055
Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2020 Aug 14;9(8):753. [Abstract]
Intensity of EPR spectra (arbitrary units) in the presence of PBN spin trapping agent in pRBCs treated with/without P505-15 (0.5 μΜ) for 24 h with/without 10-min incubation with DHA (200 µΜ) and with different concentrations (100–400 µM) of Deferasirox (DFX).
Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2020 Aug 14;9(8):753. [Abstract]
Isobolograms showing the interactions between Syk Inhibitors (P505-15 and R406) and dihydroartemisinin (DHA) and artesunate (AS) in combination with the iron chelator Deferasirox (DFX), after 24 h of incubation in the P. falciparum Palo Alto strain. Synchronized P. falciparum cultures were treated for 24 h with different concentrations (from 0.05 to 2.5 µM) of representative Syk inhibitors (P505-15 and R406) in combination with different concentrations of DHA and AS (from 0.6 to 10 nM) using a fixed concentration (50 µM) of the iron chelator Deferasirox (DFX) at the ring stage.
-
-
Cell Rep
TCF25 serves as a nutrient sensor to orchestrate metabolic adaptation and cell death by enhancing lysosomal acidification under glucose starvation. [Abstract]2025 Aug 21;44(9):116186. PMID: 40844875 -
-
Cells
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation. [Abstract]2019 Dec 20;9(1):31. PMID: 31861948 -
FASEB J
Penicillide Triggers Immunogenic Pyroptosis in Tumor Cells via Oxidative Stress/NF-κB/GSDMD Signaling Axis. [Abstract]2026 Mar 31;40(6):e71636. PMID: 41842655 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Metallomics
2024 Oct 4;16(10):mfae044. PMID: 39317669
Deferasirox purchased from MedChemExpress. Usage Cited in: Metallomics. 2024 Oct 4;16(10):mfae044. [Abstract]
Anaerobic Fe2+ competition binding assay for DFX, DFP, DMOG, and IOX3. Representative titration absorption spectra with corresponding binding profiles of Mag-Fura-2 competing for Fe2+ ions with Deferasirox.
-
Gene
Functional indications for transposase domestications - Characterization of the human piggyBac transposase derived (PGBD) activities. [Abstract]2022 Aug 5:834:146609. PMID: 35609796 -
-
Bioengineered
Platycodin D regulates high glucose-induced ferroptosis of HK-2 cells through glutathione peroxidase 4 (GPX4). [Abstract]2022 Mar;13(3):6627-6637. PMID: 35226829
Deferasirox purchased from MedChemExpress. Usage Cited in: Bioengineered. 2022 Mar;13(3):6627-6637. [Abstract]
HK-2 cells were incubated in NG or HG conditions, and both were treated with DFX and erastin. Deferasirox (200 μM) treatment markedly suppressed LDH activity.
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (267.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Cell Assay[2]
Deferasirox is dissolved in DMSO. HL-60 or KG-1 cells are treated with 0, 5, 10, 50 μM of deferasirox for 24 or 48 h, and proliferation is determined by an MTT assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration[3]
Mice: Murine leukemia cells are injected subcutaneously into the right flank of mice. Deferasirox is dissolved in distilled water and orally administered at 20 mg/kg until the cumulative dose reaches 300 mg/kg. The mice are observed and weighed daily[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45. [Content Brief]
[2]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5. [Content Brief]
[3]. Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41(6):539-46. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6784 mL | 13.3919 mL | 26.7838 mL | 66.9595 mL |
| 5 mM | 0.5357 mL | 2.6784 mL | 5.3568 mL | 13.3919 mL | |
| 10 mM | 0.2678 mL | 1.3392 mL | 2.6784 mL | 6.6960 mL | |
| 15 mM | 0.1786 mL | 0.8928 mL | 1.7856 mL | 4.4640 mL | |
| 20 mM | 0.1339 mL | 0.6696 mL | 1.3392 mL | 3.3480 mL | |
| 25 mM | 0.1071 mL | 0.5357 mL | 1.0714 mL | 2.6784 mL | |
| 30 mM | 0.0893 mL | 0.4464 mL | 0.8928 mL | 2.2320 mL | |
| 40 mM | 0.0670 mL | 0.3348 mL | 0.6696 mL | 1.6740 mL | |
| 50 mM | 0.0536 mL | 0.2678 mL | 0.5357 mL | 1.3392 mL | |
| 60 mM | 0.0446 mL | 0.2232 mL | 0.4464 mL | 1.1160 mL | |
| 80 mM | 0.0335 mL | 0.1674 mL | 0.3348 mL | 0.8370 mL | |
| 100 mM | 0.0268 mL | 0.1339 mL | 0.2678 mL | 0.6696 mL |
Deferasirox Related Classifications
HY-17359 Related Classifications
Powered by Bioz